An Iffy Future For Alkermes After Failed Trials
This article was originally published in Scrip
You may also be interested in...
Keeping Track Of Bad News: Alkermes' Depression Candidate Gets Refuse To File; Teva/Celltrion Biosimilars Land CRLs
The dark side of US FDA review news this week.
The latest drug development news and highlights from our US FDA Performance Tracker.
Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.